Seaport Therapeutics Inc SPTX
$24.86 $0.57 (2.35%) 1D
Last Updated: Sep 04, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Seaport Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of SPTX Stock
United States Health Care Small Cap No. As of September 2026, Seaport Therapeutics Inc (SPTX) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Seaport Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company is headquartered in Boston, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2026-05-01. The firm is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. The company is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.
SPTX Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Seaport Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Seaport Therapeutics Inc (SPTX) Chart
Financial Metrics & Statements of Seaport Therapeutics Inc (SPTX)
FAQ's for Seaport Therapeutics Inc (SPTX)
- As of September 2026, Seaport Therapeutics Inc SPTX is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Seaport Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Seaport Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Seaport Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Seaport Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Seaport Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Seaport Therapeutics Inc (SPTX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
